查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1372733

女性避孕市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按避孕藥物、設備、地區、競爭預測和機會細分，2018-2028F

Female Contraceptive Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Contraceptive Drugs, By Device, By Region, By Competition Forecast & Opportunities, 2018-2028F
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022年，全球女性避孕藥市場估值達150.1億美元，預計在預測期內將顯著成長，預計到2028年年複合成長率(CAGR)為6.24%。全球女性避孕藥市場包括生產分發專為女性設計的各種避孕產品和裝置，以防止意外懷孕。這個市場長期以來一直是婦女保健和計劃生育措施的重要組成部分。

主要市場促進因素

婦女賦權

市場概況
預測期 2024-2028
2022 年市場規模 150.1億美元
2028 年市場規模 216.3億美元
2023-2028 年年複合成長率 6.24%
成長最快的細分市場 口服避孕藥
最大的市場 北美洲

婦女賦權是社會變革和進步的驅動力，其影響力擴大到包括醫療保健在內的各個領域。全球女性避孕藥具市場對於生殖健康和計劃生育至關重要，受到婦女賦權的顯著影響。婦女賦權包括向婦女提供有關生殖健康和避孕選擇的資訊和教育。當女性了解情況時，她們可以根據個人目標、健康需求和生活方式做出明智的避孕選擇。賦權往往伴隨著獲得醫療服務的機會的改善。有權勢的女性更有可能尋求醫療保健資源，包括計劃生育診所和避孕措施。這種需求的增加可以刺激市場成長，促使製藥公司投資於新的和改進的避孕選擇的研發。經濟獨立和賦權使婦女能夠負擔得起避孕藥具和計劃生育服務。財務自主權使她們能夠對自己的生殖健康做出選擇，而不必只依賴伴侶或家庭成員。這種財務自由有助於增加避孕藥具的使用和市場的成長。獲得權力的女性更有可能挑戰和改變有關避孕和計劃生育的社會規範和態度。透過倡導生殖權利並打破與避孕藥具使用相關的恥辱，女性賦權可以為那些尋求避孕藥具的人創造一個更具支持性的環境。賦權通常會帶來計劃和行動。賦予婦女權力和致力於婦女權利的組織可以推動有關計劃生育和避孕藥具重要性的宣傳活動。此類措施有助於教育和激勵個人將避孕視為可行的選擇。被賦權的女性常常成為所在社區的榜樣。當他們做出有關避孕的明智決定時，可以激勵其他人也這樣做。這種連鎖反應可能會導致社區和地區對避孕藥具的更高需求。

人口成長和都市化

多年來，全球女性避孕市場顯著成長，而這項擴張的關鍵促進因素是人口成長和都市化之間的相互作用。隨著世界人口持續增加，居住在城市地區的人口比例不斷增加，對有效計劃生育和女性避孕藥具的需求激增。都市化伴隨著醫療保健服務的改善。在城市地區，個人通常更容易前往診所、醫院和計劃生育中心，那裡提供避孕藥具。這些服務的鄰近性鼓勵更多的人，尤其是婦女，尋求和使用避孕藥具。由於居住空間有限、生活成本上升和職業抱負等因素，城市化往往導致家庭規模縮小。隨著城市家庭優先考慮更小、更易於管理的家庭規模，對有效避孕藥具的計劃和間隔生育的需求更大。城市地區通常擁有更好的教育基礎設施，從而提高人們對計劃生育和避孕方法重要性的認知。城市中心的人們更有可能了解自己的生殖健康選擇，因此選擇使用女性避孕藥來防止意外懷孕。城市化往往帶來經濟機會和更高的生活水準。隨著城市地區的個人和家庭努力實現財務穩定和職業發展，他們傾向於推遲生育並優先考慮避孕，作為計劃生育和確保經濟未來的手段。城市環境往往促進性別平等和婦女賦權，使婦女能夠對其生殖健康做出選擇。獲得權力的女性更有可能尋求和使用避孕藥具，從而促進女性避孕藥具市場的成長。

改變社會規範

全球女性避孕市場正在不斷發展，這不僅受到技術和醫療保健進步的推動，而且還受到社會規範和避孕態度轉變的推動。隨著世界各地社會的不斷發展，人們對計劃生育和生殖健康的看法也不斷發展。社會規範的改變正在逐漸減少與避孕相關的恥辱。在許多社會，有關計劃生育和避孕藥具使用的討論一度被視為禁忌。然而，隨著對話變得更加開放和接受，人們越來越願意尋求避孕選擇，從而推動市場成長。社會規範的改變往往伴隨著婦女賦權的發生。隨著女性對自己的生活（包括生育選擇）擁有更大的控制權，她們更有可能尋求和使用避孕藥。賦權婦女正在倡導她們的生殖權利和選擇，從而促進了對女性避孕藥具的需求增加。社會變革催生了促進計劃生育和生殖健康的教育措施。這些計劃旨在讓女性和男性了解避孕選擇、福利和負責任的計劃生育做法。更多知識鼓勵避孕藥具的使用，進而促進市場成長。規範的改變，例如推遲生育以專注於職業或個人目標，導致對避孕藥具的需求增加。夫婦們積極選擇推遲建立家庭，直到他們在經濟和情感上做好準備。這種延遲通常需要有效的避孕措施。

全球健康議題

全球健康議題一直是各個醫療保健產業發展和擴張的驅動力，全球女性避孕市場也不例外。人們對人口控制、預防意外懷孕和性傳染感染（STI）傳播的認知不斷增強，推動了女性避孕市場的創新。推動女性避孕市場成長的主要全球健康問題之一是有效控制人口的需要。隨著世界人口持續激增，特別是在發展中國家，人們越來越意識到這對資源、醫療保健系統和環境造成的壓力。世界各地的政策制定者和醫療保健組織都認知到賦予婦女計劃生育選擇權的重要性。女性避孕藥具提供了控制家庭規模的可靠方法，使女性能夠根據自己的喜好和情況計劃懷孕並間隔懷孕。這不僅可以讓家庭更加健康，還有助於遏制人口過剩，這是許多國家面臨的關鍵問題。因此，女性避孕藥具的供應和可近性已成為各國政府和國際衛生組織的優先事項，推動了市場成長。意外懷孕可能會產生深遠的社會、經濟和健康後果。它們可能導致教育延遲、職業機會受到限制、經濟壓力增加，甚至孕產婦和嬰兒死亡率更高。

主要市場挑戰

訪問和意識有限

全球女性避孕藥具市場面臨的最重大挑戰之一是取得和意識有限，特別是在低收入和邊緣化社區。由於地理、經濟或文化障礙，世界各地的許多婦女仍然無法獲得負擔得起且可靠的避孕藥。在某些情況下，女性根本不知道可用的避孕方法及其好處。

恥辱和文化障礙

文化和社會規範可能會對避孕藥具的使用造成重大障礙，尤其是在保守或傳統社會中。圍繞避孕的恥辱和對判斷的恐懼可能會阻止女性尋求和使用避孕藥具。這些文化障礙往往根深蒂固，需要採取全面的策略來解決。

為了消除恥辱和文化障礙，教育和宣傳活動至關重要。這些努力旨在改變社會對避孕的看法和態度，同時強調其在促進計劃生育和婦女健康方面的重要性。當地社區的參與和文化敏感的方法對於應對這些挑戰也至關重要。

產品安全和副作用

女性避孕市場面臨的另一個挑戰是對產品安全和潛在副作用的擔憂。雖然避孕藥具通常安全有效，但有些女性可能會出現副作用或不良反應。對這些副作用的恐懼可能會阻止一些女性使用避孕藥具。

為了應對這項挑戰，製藥公司和醫療保健提供者正在不斷研究和開發安全性更高、副作用更少的新避孕方法。此外，醫療保健專業人員正在努力為女性提供更好的諮詢和支持，幫助她們根據個人健康和偏好做出避孕選擇的明智決定。

主要市場趨勢

副作用減少的荷爾蒙避孕藥

女性避孕藥市場最有前景的趨勢之一是開發副作用減少的荷爾蒙避孕藥。製藥公司正在投資研究開發避孕藥，以有效預防懷孕，同時最大限度地減少體重增加、情緒波動和性慾下降等常見副作用。這些創新旨在改善整體用戶體驗，並鼓勵更多女性選擇荷爾蒙避孕藥作為首選方法。

長效可逆避孕藥 (LARC)

長效可逆避孕藥 (LARC) 作為一種方便、有效的女性選擇而越來越受歡迎。 LARC 包括子宮內避孕器 (IUD) 和植入式避孕器，只需一次插入即可避孕數年。隨著女性尋求適合她們忙碌生活方式的可靠、低維護的避孕選擇，這一趨勢預計將持續下去。

數位健康和​​避孕應用程式

數位健康和​​科技融入女性避孕市場是一個值得注意的趨勢。智慧型手機應用程式和穿戴式裝置正在開發中，以幫助女性追蹤月經週期和生育能力，為自然計劃生育方法提供有價值的資訊。這些應用程式提供了便利，並且可以與傳統避孕方法一起使用以增加保證。

永續且環保的避孕藥具

隨著環保意識的不斷增強，永續和環保的避孕選擇出現了新興趨勢。製造商正在探索可生物分解的材料和包裝，以減少與避孕產品相關的浪費。此外，重點是開發環境足跡最小的避孕藥。

細分市場洞察

避孕藥見解

根據避孕藥類別，由於幾個令人信服的原因，口服避孕藥細分市場將在 2022 年成為全球女性避孕藥市場的主導者。首先也是最重要的是，它們提供了一種方便且被廣泛接受的節育方法，使女性能夠透過簡單的每日藥丸來掌控自己的生殖健康。這種易用性符合許多女性在當今忙碌而忙碌的生活方式。此外，口服避孕藥具有良好的安全性記錄和相對較低的副作用發生率，使其成為廣大女性值得信賴的選擇。此外，正在進行的研究和開發工作繼續完善這些藥物，解決減少副作用和提高療效等問題。組合藥丸和純黃體素藥丸的可用性進一步滿足個人喜好和醫療需求。隨著全球醫療保健服務的普及和計劃生育意識的提高，口服避孕藥可能會保持其在全球市場的主導地位，為女性提供可靠且適應性強的避孕選擇。

設備洞察

由於多種因素，包括意外懷孕發生率上升、臨床療效高以及在人群中廣泛採用，預計女性避孕植入劑市場將出現成長。在皮下植入避孕劑類別中，預計依托孕烯植入劑將大幅擴張。依托孕烯是一種抑制排卵的激素，也會引起子宮頸黏液和子宮內膜的變化，使精子到達子宮和受精卵附著變得更加困難。皮下依托孕烯植入劑被用作避孕方法來防止懷孕，藥物包含在插入上臂皮膚下方的小塑膠棒中。棒子逐漸將藥物釋放到體內，提供長達三年的連續避孕效果。預計在預測期內，公司越來越注重實施各種業務策略，例如推出新產品、擴大不同國家的產品供應、進行合併和進行公司分拆，預計該市場的成長將進一步推動。

區域洞察

預計在整個預測期內，北美將保持其在女性避孕器具市場的主導地位，這主要是由於幾個因素。其中包括意外懷孕和高墮胎率的增加、先進的醫療基礎設施的存在、避孕藥物和設備的高採用率以及越來越多的政府舉措。美國和加拿大的女性人口中有很大一部分屬於育齡群體。因此，意外懷孕和墮胎率的上昇在推動該地區市場擴張方面發揮關鍵作用。例如，古特馬赫研究所2022年3月的資料顯示，2015年至2019年間，北美每年總共有566萬例懷孕，其中259萬例意外懷孕，88.6萬例墮胎。此外，皮尤研究中心2022 年6 月發布的統計數據顯示，美國墮胎案件有所增加，2020 年美國有930,160 起，而2019 年為916,460 起。預計墮胎案件的激增將推動對各種避孕方法的需求防止意外懷孕，進而推動市場成長。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球女性避孕市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依避孕藥（口服避孕藥、避孕針劑、外用避孕藥、殺精劑）
    • 依裝置分類（女用保險套、隔膜和帽子、陰道環、避孕海綿、皮下避孕植入物、子宮內避孕裝置 (IUCD) 等）
    • 按地區
    • 按公司分類 (2022)
  • 產品市場地圖
    • 透過避孕藥
    • 按設備
    • 按地區

第 6 章：北美女性避孕市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依避孕藥（口服避孕藥、避孕針劑、外用避孕藥、殺精劑）
    • 依裝置分類（女用保險套、隔膜和帽子、陰道環、避孕海綿、皮下避孕植入物、子宮內避孕裝置 (IUCD) 等）
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲女性避孕市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依避孕藥（口服避孕藥、避孕針劑、外用避孕藥、殺精劑）
    • 依裝置分類（女用保險套、隔膜和帽子、陰道環、避孕海綿、皮下避孕植入物、子宮內避孕裝置 (IUCD) 等）
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙

第 8 章：亞太地區女性避孕市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依避孕藥（口服避孕藥、避孕針劑、外用避孕藥、殺精劑）
    • 依裝置分類（女用保險套、隔膜和帽子、陰道環、避孕海綿、皮下避孕植入物、子宮內避孕裝置 (IUCD) 等）
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國

第 9 章：南美洲女性避孕市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依避孕藥（口服避孕藥、避孕針劑、外用避孕藥、殺精劑）
    • 依裝置分類（女用保險套、隔膜和帽子、陰道環、避孕海綿、皮下避孕植入物、子宮內避孕裝置 (IUCD) 等）
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲女性避孕市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依避孕藥（口服避孕藥、避孕針劑、外用避孕藥、殺精劑）
    • 依裝置分類（女用保險套、隔膜和帽子、陰道環、避孕海綿、皮下避孕植入物、子宮內避孕裝置 (IUCD) 等）
    • 按國家/地區
  • MEA：國家分析
    • 南非女性避孕
    • 沙烏地阿拉伯 女性避孕
    • 阿拉伯聯合大公國女性避孕
    • 科威特女性避孕

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • 商業概覽
  • 產品供應
  • 最近的發展
  • 財務（據報導）
  • 主要人員
  • SWOT分析
    • Bayer AG
    • Mayer Laboratories Inc
    • Pfizer Inc
    • Mylan Pharmaceuticals Inc
    • Teva Pharmaceutical Industries Ltd
    • Organon & Co.
    • Agile Therapeutics Inc
    • Lupin Pharmaceuticals Inc
    • The Female Health Company
    • FUJI LATEX CO.,LTD.

第 15 章：策略建議

第 16 章：關於我們與免責聲明

簡介目錄
Product Code: 16167

In 2022, the Global Female Contraceptive Market achieved a valuation of USD 15.01 billion and is poised for remarkable growth in the projected period, with an expected Compound Annual Growth Rate (CAGR) of 6.24% through 2028. The global female contraceptive market encompasses the production and distribution of a diverse range of contraceptive products and devices tailored for women to prevent unintended pregnancies. This market has long been an essential element of women's healthcare and family planning initiatives.

Key Market Drivers

Women's Empowerment

Market Overview
Forecast Period2024-2028
Market Size 2022USD 15.01 Billion
Market Size 2028USD 21.63 Billion
CAGR 2023-20286.24%
Fastest Growing SegmentOral Contraceptives
Largest MarketNorth America

Women's empowerment is a driving force for social change and progress, extending its influence on various sectors, including healthcare. The global female contraceptive market, vital for reproductive health and family planning, is significantly impacted by women's empowerment. Women's empowerment involves providing women with information and education about their reproductive health and contraceptive options. When women are well-informed, they can make informed choices about contraception that align with their personal goals, health needs, and lifestyles. Empowerment often comes with improved access to healthcare services. Empowered women are more likely to seek out healthcare resources, including family planning clinics and contraception. This increased demand can stimulate market growth, prompting pharmaceutical companies to invest in research and development of new and improved contraceptive options. Economic independence and empowerment enable women to afford contraceptives and family planning services. Financial autonomy allows them to make choices about their reproductive health without relying solely on their partners or family members. This financial freedom contributes to increased contraceptive usage and market growth. Empowered women are more likely to challenge and change societal norms and attitudes surrounding contraception and family planning. By advocating for reproductive rights and breaking down stigmas associated with contraceptive use, empowered women can create a more supportive environment for those seeking contraceptives. Empowerment often leads to advocacy and activism. Empowered women and organizations dedicated to women's rights can drive awareness campaigns about family planning and the importance of contraceptives. Such initiatives help educate and motivate individuals to consider contraception as a viable option. Empowered women often serve as role models within their communities. When they make informed decisions about contraception, it can inspire others to do the same. This ripple effect can contribute to a higher demand for contraceptives within communities and regions.

Growing Population and Urbanization

The global female contraceptive market has seen significant growth over the years, and one key driver of this expansion is the interplay between population growth and urbanization. As the world's population continues to increase, with a growing proportion residing in urban areas, the demand for effective family planning and female contraceptives has surged. Urbanization is accompanied by improved access to healthcare services. In urban areas, individuals often have easier access to clinics, hospitals, and family planning centers where contraceptive options are readily available. The proximity of these services encourages more people, especially women, to seek and use contraceptives. Urbanization often leads to smaller family sizes due to factors such as limited living space, higher living costs, and career aspirations. As urban families prioritize smaller and more manageable family sizes, there is a greater demand for effective contraceptives to plan and space births. Urban areas typically have better educational infrastructure, leading to increased awareness about the importance of family planning and contraceptive methods. People in urban centers are more likely to be informed about their reproductive health options and, as a result, choose to use female contraceptives to prevent unplanned pregnancies. Urbanization often brings about economic opportunities and higher standards of living. As individuals and families in urban areas strive for financial stability and career advancement, they tend to delay childbirth and prioritize contraception as a means of family planning and securing their economic future. Urban environments often promote gender equality and women's empowerment, enabling women to make choices about their reproductive health. Empowered women are more likely to seek and use contraceptives, contributing to the growth of the female contraceptive market.

Changing Social Norms

The global female contraceptive market is evolving, driven not only by advancements in technology and healthcare but also by shifting social norms and attitudes towards contraception. As societies around the world continue to evolve, so do the perceptions of family planning and reproductive health. Changing social norms is gradually reducing the stigma associated with contraception. In many societies, discussions surrounding family planning and contraceptive use were once considered taboo. However, as conversations become more open and accepting, individuals are increasingly comfortable seeking contraceptive options, thus driving market growth. Changing social norms often accompany the empowerment of women. As women gain greater control over their lives, including their reproductive choices, they are more likely to seek and use contraceptives. Empowered women are advocating for their reproductive rights and choices, contributing to an increased demand for female contraceptives. Societal changes have led to educational initiatives that promote family planning and reproductive health. These programs aim to inform both women and men about contraceptive options, benefits, and responsible family planning practices. Greater knowledge encourages the use of contraceptives, which boosts market growth. Changing norms, such as delaying parenthood to focus on careers or personal goals, have resulted in a higher demand for contraceptives. Couples are actively choosing to postpone starting families until they feel financially and emotionally prepared. This delay often requires effective contraception.

Global Health Concerns

Global health concerns have been a driving force behind the development and expansion of various healthcare sectors, and the global female contraceptive market is no exception. The growing awareness of population control, the prevention of unintended pregnancies, and the spread of sexually transmitted infections (STIs) has fueled innovation in the female contraceptive market. One of the primary global health concerns that have driven the growth of the female contraceptive market is the need for effective population control. As the world's population continues to surge, particularly in developing countries, there is a growing awareness of the strain this puts on resources, healthcare systems, and the environment. Policymakers and healthcare organizations worldwide recognize the importance of empowering women with choices for family planning. Female contraceptives offer a reliable means of controlling family size, allowing women to plan pregnancies and space them according to their preferences and circumstances. This not only leads to healthier families but also helps in curbing overpopulation, a critical issue facing many countries. The availability and accessibility of female contraceptives have thus become a priority for governments and international health organizations, driving market growth. Unintended pregnancies can have far-reaching social, economic, and health consequences. They can result in delayed education, restricted career opportunities, increased financial stress, and even higher rates of maternal and infant mortality.

Key Market Challenges

Limited Access and Awareness

One of the most significant challenges facing the global female contraceptive market is limited access and awareness, particularly in low-income and marginalized communities. Many women around the world still lack access to affordable and reliable contraceptives due to geographical, financial, or cultural barriers. In some cases, women are simply unaware of the available contraceptive options and their benefits.

To overcome this challenge, efforts are being made to improve education and awareness about contraceptives, especially in underserved regions. NGOs, governments, and international organizations are working together to increase access to family planning services, ensuring that women have the information and resources they need to make informed decisions about their reproductive health.

Stigma and Cultural Barriers

Cultural and societal norms can create significant barriers to contraceptive use, especially in conservative or traditional societies. Stigma surrounding contraception and the fear of judgment can deter women from seeking and using contraceptives. These cultural barriers are often deeply rooted and require comprehensive strategies to address.

To combat stigma and cultural barriers, education and advocacy campaigns are essential. These efforts aim to change societal perceptions and attitudes toward contraception while emphasizing its importance in promoting family planning and women's health. Local community engagement and culturally sensitive approaches are also crucial in addressing these challenges.

Product Safety and Side Effects

Another challenge faced by the female contraceptive market is concerns related to product safety and potential side effects. While contraceptives are generally safe and effective, some women may experience side effects or adverse reactions. The fear of these side effects can discourage some women from using contraceptives.

To address this challenge, pharmaceutical companies and healthcare providers are continually researching and developing new contraceptive methods with improved safety profiles and fewer side effects. Additionally, healthcare professionals are working to provide better counseling and support to women, helping them make informed decisions about contraceptive options based on their individual health and preferences.

Key Market Trends

Hormonal Contraceptives with Reduced Side Effects

One of the most promising trends in the female contraceptive market is the development of hormonal contraceptives with reduced side effects. Pharmaceutical companies are investing in research to create contraceptives that offer effective pregnancy prevention while minimizing common side effects like weight gain, mood swings, and decreased libido. These innovations are aimed at improving the overall user experience and encouraging more women to choose hormonal contraceptives as their preferred method.

Long-Acting Reversible Contraceptives (LARCs)

Long-Acting Reversible Contraceptives (LARCs) are gaining popularity as a convenient and effective option for women. LARCs include intrauterine devices (IUDs) and contraceptive implants, which can provide contraception for several years with a single insertion. This trend is expected to continue as women seek reliable, low-maintenance contraceptive options that fit their busy lifestyles.

Digital Health and Contraceptive Apps

The integration of digital health and technology into the female contraceptive market is a noteworthy trend. Smartphone applications and wearable devices are being developed to help women track their menstrual cycles and fertility, providing valuable information for natural family planning methods. These apps offer convenience and can be used alongside traditional contraceptive methods for added assurance.

Sustainable and Eco-Friendly Contraceptives

As environmental awareness continues to grow, there is an emerging trend toward sustainable and eco-friendly contraceptive options. Manufacturers are exploring biodegradable materials and packaging, reducing waste associated with contraceptive products. Additionally, there is a focus on developing contraceptives with a minimal environmental footprint.

Segmental Insights

Contraceptive Drugs Insights

Based on the category of Contraceptive Drugs, the Oral Contraceptives segment emerged as the dominant player in the global market for female contraceptive market in 2022 for several compelling reasons. First and foremost, they offer a convenient and widely accepted method of birth control, allowing women to take charge of their reproductive health with a simple daily pill. This ease of use aligns with the busy and on-the-go lifestyles of many women today. Additionally, oral contraceptives have a well-established safety record and a relatively low incidence of side effects, making them a trusted choice for a broad spectrum of women. Moreover, ongoing research and development efforts continue to refine these medications, addressing concerns such as reducing side effects and increasing efficacy. The availability of both combination pills and progestin-only pills further caters to individual preferences and medical needs. As access to healthcare services and awareness of family planning grow worldwide, oral contraceptives are likely to maintain their dominance in the global market, offering a reliable and adaptable contraceptive option for women.

Device Insights

Anticipated growth in the female contraceptive market is expected within the sub-dermal contraceptive implants category due to several factors, including a rising incidence of unintended pregnancies, high clinical efficacy, and widespread adoption among the population. Within the sub-dermal contraceptive implants category, it is foreseen that Etonogestrel implants will experience substantial expansion. Etonogestrel, a hormone that inhibits ovulation, also induces changes in cervical mucus and the uterine lining, making it more challenging for sperm to reach the uterus and for a fertilized egg to attach. Subdermal Etonogestrel implants are employed as a contraceptive method to prevent pregnancy, with the medication contained in a small plastic rod inserted beneath the skin of the upper arm. This rod gradually releases the medication into the body, providing continuous contraception for up to three years. The market's growth is further expected to receive a boost from the increasing focus of companies on implementing various business strategies, such as launching new products, expanding product availability in different countries, engaging in mergers, and undertaking company spin-offs, during the forecast period.

Regional Insights

North America is projected to maintain its dominance in the female contraceptive devices market throughout the forecast period, primarily due to several factors. These include the increasing instances of unintended pregnancies and high abortion rates, the presence of advanced healthcare infrastructure, a high rate of adoption of contraceptive drugs and devices, and a growing number of government initiatives. A significant portion of the female population in the United States and Canada falls within the reproductive age group. Consequently, the rising occurrences of unwanted pregnancies and abortion rates play a pivotal role in propelling market expansion in the region. For instance, data from the Guttmacher Institute in March 2022 revealed that between 2015 and 2019, North America witnessed a total of 5,660,000 pregnancies annually, with 2,590,000 of them being unwanted, and 886,000 resulting in abortion. Moreover, statistics published by the Pew Research Center in June 2022 showed an increase in abortion cases, with 930,160 recorded in the United States in 2020 compared to 916,460 in 2019. This surge in abortion cases is anticipated to drive the demand for various contraceptive methods to prevent unwanted pregnancies, thereby fueling market growth.

Key Market Players

  • Bayer AG
  • Mayer Laboratories Inc
  • Pfizer Inc
  • Mylan Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd
  • Organon & Co.
  • Agile Therapeutics Inc
  • Lupin Pharmaceuticals Inc
  • The Female Health Company
  • FUJI LATEX CO.,LTD.

Report Scope:

In this report, the Global Female Contraceptive Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Female Contraceptive Market, By Contraceptive Drugs:

  • Oral Contraceptives
  • Contraceptive Injections
  • Topical Contraceptives
  • Spermicides

Female Contraceptive Market, By Device:

  • Female Condoms
  • Diaphragms and Caps
  • Vaginal Rings
  • Contraceptive Sponges
  • Sub-dermal Contraceptive Implants
  • Intra Uterine Contraceptive Devices (IUCDs)
  • Others

Female Contraceptive Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Female Contraceptive Market.

Available Customizations:

  • Global Female Contraceptive market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Female Contraceptive Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 5.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Product Market Map
    • 5.3.1. By Contraceptive Drugs
    • 5.3.2. By Device
    • 5.3.3. By Region

6. North America Female Contraceptive Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 6.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Female Contraceptive Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Contraceptive Drugs
        • 6.3.1.2.2. By Device
    • 6.3.2. Canada Female Contraceptive Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Contraceptive Drugs
        • 6.3.2.2.2. By Device
    • 6.3.3. Mexico Female Contraceptive Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Contraceptive Drugs
        • 6.3.3.2.2. By Device

7. Europe Female Contraceptive Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 7.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Female Contraceptive Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Contraceptive Drugs
        • 7.3.1.2.2. By Device
    • 7.3.2. United Kingdom Female Contraceptive Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Contraceptive Drugs
        • 7.3.2.2.2. By Device
    • 7.3.3. France Female Contraceptive Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Contraceptive Drugs
        • 7.3.3.2.2. By Device
    • 7.3.4. Italy Female Contraceptive Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Contraceptive Drugs
        • 7.3.4.2.2. By Device
    • 7.3.5. Spain Female Contraceptive Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Contraceptive Drugs
        • 7.3.5.2.2. By Device

8. Asia-Pacific Female Contraceptive Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 8.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Female Contraceptive Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Contraceptive Drugs
        • 8.3.1.2.2. By Device
    • 8.3.2. Japan Female Contraceptive Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Contraceptive Drugs
        • 8.3.2.2.2. By Device
    • 8.3.3. India Female Contraceptive Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Contraceptive Drugs
        • 8.3.3.2.2. By Device
    • 8.3.4. Australia Female Contraceptive Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Contraceptive Drugs
        • 8.3.4.2.2. By Device
    • 8.3.5. South Korea Female Contraceptive Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Contraceptive Drugs
        • 8.3.5.2.2. By Device

9. South America Female Contraceptive Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 9.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Female Contraceptive Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Contraceptive Drugs
        • 9.3.1.2.2. By Device
    • 9.3.2. Argentina Female Contraceptive Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Contraceptive Drugs
        • 9.3.2.2.2. By Device
    • 9.3.3. Colombia Female Contraceptive Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Contraceptive Drugs
        • 9.3.3.2.2. By Device

10. Middle East and Africa Female Contraceptive Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 10.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Female Contraceptive Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Contraceptive Drugs
        • 10.3.1.2.2. By Device
    • 10.3.2. Saudi Arabia Female Contraceptive Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Contraceptive Drugs
        • 10.3.2.2.2. By Device
    • 10.3.3. UAE Female Contraceptive Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Contraceptive Drugs
        • 10.3.3.2.2. By Device
    • 10.3.4. Kuwait Female Contraceptive Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Contraceptive Drugs
        • 10.3.4.2.2. By Device

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. Bayer AG
    • 14.6.2. Mayer Laboratories Inc
    • 14.6.3. Pfizer Inc
    • 14.6.4. Mylan Pharmaceuticals Inc
    • 14.6.5. Teva Pharmaceutical Industries Ltd
    • 14.6.6. Organon & Co.
    • 14.6.7. Agile Therapeutics Inc
    • 14.6.8. Lupin Pharmaceuticals Inc
    • 14.6.9. The Female Health Company
    • 14.6.10. FUJI LATEX CO.,LTD.

15. Strategic Recommendations

16. About Us & Disclaimer